A new Michigan State University (MSU) study reveals an inexpensive Type-2 diabetes drug may prevent natural and man-made chemicals from stimulating the growth of breast cancer cells, MSU News recently reported.
James Trosko, a professor of pediatrics and human development in the College of Human Medicine at MSU, lead the study with South Korea’s Seoul National University. The research is available in the current edition of PLoS One.
The study proves long-term use of the drug metformin to treat Type-2 diabetes reduces the risk of diabetes-associated cancers, such as breast cancers.
“People with Type-2 diabetes are known to be at high risk for several diabetes-associated cancers, such as breast, liver and pancreatic cancers,” said Trosko. “While metformin has been shown in population studies to reduce the risk of these cancers, there was no evidence of how it worked.”
Trosko concluded, “…[T]his study reveals the need to determine if the drug might be used as a preventive drug and for individuals who have no indication of any existing cancers.”